19 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
2
Design, synthesis, and biological characterization of proteolysis targeting chimera (PROTACs) for the ataxia telangiectasia and RAD3-related (ATR) kinase.
Martin-Luther-University of Halle-Wittenberg
35
Discovery of Preclinical Candidate AD1058 as a Highly Potent, Selective, and Brain-Penetrant ATR Inhibitor for the Treatment of Advanced Malignancies.
Shanghai Institute of Materia Medica
30
Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500).
Repare Therapeutics, Inc.
56
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
Hubei Polytechnic University
30
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.
Bayer
30
Synthetic Lethality through the Lens of Medicinal Chemistry.
Istituto Italiano Di Tecnologia
156
1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
Chong Kun Dang Pharmaceutical
73
2,3-DIHYDROBENZO[B][1,4]DIOXIN-6-YL CONTAINING COMPOUNDS USEFUL AS IMMUNOMODULATORS
Bristol Myers Squibb
11
Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine
Kronos Bio
310
Substituted pyrazoloazepin-8-ones and their use as phosphodiesterase inhibitors
Leo Pharma
18
Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents
Zenji Research Laboratories
9
Sulfur-containing compounds targeting vesicular acetylcholine transporter
Washington University